As far as Roche CEO Severin Schwan (photo) is concerned, the European economic crisis will trigger deep cuts in healthcare spending, leaving room for only two types of Big Pharma players: Generic drugmakers with the economies of scale needed to market huge volumes of cheap drugs and innovators that can conjure a new generation of therapies that offer markedly better outcomes for patients. Report